← Leaderboards
Vijay H Shah
Mayo Clinic Coll Of Medicine, Rochester
$27,167,769
Attributed
$31,999,469
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,999,469 · 20
By mechanism
R01$13,969,137 · 6
U01$9,186,356 · 4
R37$2,624,352 · 1
T32$2,148,712 · 1
P30$1,362,330 · 2
UH3$1,145,007 · 1
Top collaborators
- Douglas A. Simonetto10 shared
- Patrick S. Kamath6 shared
- Meng Yin6 shared
- Harmeet Malhi5 shared
- Daniel J. Tschumperlin4 shared
- Victor M. Karpyak2 shared
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverMorbidity - Disease RateBaseMolecularMortalitySignal TransductionInnovationCirrhosisIn VivoMediatingHepatic Stellate CellLiver InjuryAlcoholic HepatitisPathway InteractionsProteinsFibrosisMagnetic Resonance ElastographyClinical TrialsResearch PersonnelPathogenesisClinicFutureAlcoholsEffective Therapy
Grant awards (109)
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$397,500
U01 · FY2025 · DK · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2025 · AA · contact PI
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) â Mayo Clinic$355,080
U01 · FY2025 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2024 · AA · contact PI
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) â Mayo Clinic$355,080
U01 · FY2024 · AA · contact PI
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$239,180
U01 · FY2024 · DK · contact PI
Administrative Core$135,737
P30 · FY2024 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$357,750
R01 · FY2023 · DK · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2023 · AA · contact PI
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$210,405
U01 · FY2023 · DK · contact PI
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography$381,669
UH3 · FY2022 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$369,000
U01 · FY2022 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2022 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$357,750
R01 · FY2022 · DK · contact PI
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$297,083
U01 · FY2022 · DK · contact PI
Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development$245,768
U01 · FY2022 · AA · contact PI
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2022 · AA · contact PI
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography$381,669
UH3 · FY2021 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$380,152
U01 · FY2021 · AA · contact PI
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$366,103
U01 · FY2021 · DK · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2021 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$357,750
R01 · FY2021 · DK · contact PI
Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development$245,768
U01 · FY2021 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)$120,102
R37 · FY2021 · AA · contact PI
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2021 · AA · contact PI
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography$381,669
UH3 · FY2020 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$380,152
U01 · FY2020 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$357,750
R01 · FY2020 · DK · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2020 · AA · contact PI
Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development$245,768
U01 · FY2020 · AA · contact PI
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2020 · AA · contact PI
Targeting matrix stiffness in lung and liver fibrosis$532,636
R01 · FY2019 · HL
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$380,152
U01 · FY2019 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R37 · FY2019 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$357,750
R01 · FY2019 · DK · contact PI
Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development$247,878
U01 · FY2019 · AA · contact PI
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography$217,353
UH2 · FY2019 · AA · contact PI
Noninvasive assessment of alcoholic hepatitis effects in promoting age-related cognitive decline with multiparametric magnetic resonance elastography (MRE) imaging$217,353
UH2 · FY2019 · AA · contact PI
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2019 · AA · contact PI
Targeting matrix stiffness in lung and liver fibrosis$538,996
R01 · FY2018 · HL
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$369,000
U01 · FY2018 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R01 · FY2018 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$345,825
R01 · FY2018 · DK · contact PI
Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development$250,000
U01 · FY2018 · AA · contact PI
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography$218,625
UH2 · FY2018 · AA · contact PI
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2018 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 5/9$4,780
U01 · FY2018 · AA · contact PI
TREAT-Mayo$625,003
U01 · FY2017 · AA · contact PI
Targeting matrix stiffness in lung and liver fibrosis$538,996
R01 · FY2017 · HL
Molecular Mechanisms of Liver Fibrosis$357,750
R01 · FY2017 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$345,825
R01 · FY2017 · DK · contact PI
TREAT-Mayo$625,003
U01 · FY2016 · AA · contact PI
Targeting matrix stiffness in lung and liver fibrosis$540,586
R01 · FY2016 · HL
Molecular Mechanisms of Liver Fibrosis$357,750
R01 · FY2016 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$345,825
R01 · FY2016 · DK · contact PI
TREAT-Mayo$591,431
U01 · FY2015 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$347,017
R01 · FY2015 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$345,825
R01 · FY2015 · DK · contact PI
TREAT-Mayo$589,343
U01 · FY2014 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$347,018
R01 · FY2014 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$345,825
R01 · FY2014 · DK · contact PI
TREAT-Mayo$522,045
U01 · FY2013 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$332,708
R01 · FY2013 · AA · contact PI
Multidisciplinary Training in Digestive Diseases$320,455
T32 · FY2013 · DK · contact PI
CLINICAL CORE$228,858
P30 · FY2013 · DK · contact PI
TREAT-Mayo$34,999
U01 · FY2013 · AA · contact PI
TREAT-Mayo$484,683
U01 · FY2012 · AA · contact PI
Molecular Mechanisms of Liver Fibrosis$357,750
R01 · FY2012 · AA · contact PI
Molecular Mechanisms of Portal Hypertension$314,697
R01 · FY2012 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$295,963
T32 · FY2012 · DK · contact PI
CLINICAL CORE$250,849
P30 · FY2012 · DK · contact PI
Mechanisms of Nitric Oxide Signaling in Vascular Remodeling$377,750
R01 · FY2011 · HL · contact PI
Molecular Mechanisms of Portal Hypertension$314,697
R01 · FY2011 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$291,053
T32 · FY2011 · DK · contact PI
CLINICAL CORE$246,259
P30 · FY2011 · DK · contact PI
Mechanisms of Nitric Oxide Signaling in Vascular Remodeling$377,750
R01 · FY2010 · HL · contact PI
Molecular Mechanisms of Portal Hypertension$317,877
R01 · FY2010 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$272,544
T32 · FY2010 · DK · contact PI
CLINICAL CORE$250,314
P30 · FY2010 · DK · contact PI
Mechanisms of Nitric Oxide Signaling in Vascular Remodeling$377,750
R01 · FY2009 · HL · contact PI
Molecular Mechanisms of Portal Hypertension$321,088
R01 · FY2009 · DK · contact PI
CLINICAL CORE$250,313
P30 · FY2009 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$245,693
T32 · FY2009 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$99,348
R01 · FY2009 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$16,878
R01 · FY2009 · DK · contact PI
Mechanisms of Nitric Oxide Signaling in Vascular Remodeling$377,750
R01 · FY2008 · HL · contact PI
Molecular Mechanisms of Portal Hypertension$321,088
R01 · FY2008 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$220,526
T32 · FY2008 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$377,750
R56 · FY2007 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$241,038
T32 · FY2007 · DK · contact PI
Multidisciplinary Training in Digestive Diseases$261,440
T32 · FY2006 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$246,933
R01 · FY2006 · DK · contact PI
Failure of FasL Mediated Pathways in Tumor Angiogenesis$207,081
R01 · FY2006 · DK · contact PI
Molecular Mechanisms of Portal Hypertension$252,875
R01 · FY2005 · DK
Failure of FasL Mediated Pathways in Tumor Angiogenesis$212,245
R01 · FY2005 · DK
Inhibition of TNF in Patients with Alcoholic Hepatitis$184,500
R01 · FY2005 · AA
A RANDOMIZED CONTROL OF ETANERCEPT IN THE TREATMENT OF ALCOHOLIC HEPATITIS$1,185
M01 · FY2005 · RR
Molecular Mechanisms of Portal Hypertension$252,875
R01 · FY2004 · DK
Failure of FasL Mediated Pathways in Tumor Angiogenesis$215,373
R01 · FY2004 · DK
Inhibition of TNF in Patients with Alcoholic Hepatitis$184,500
R01 · FY2004 · AA
Molecular Mechanisms of Portal Hypertension$252,875
R01 · FY2003 · DK
Inhibition of TNF in Patients with Alcoholic Hepatitis$219,000
R01 · FY2003 · AA
Failure of FasL Mediated Pathways in Tumor Angiogenesis$216,750
R01 · FY2003 · DK
Molecular Mechanisms of Portal Hypertension$180,625
R01 · FY2002 · DK
REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION$133,780
K08 · FY2002 · DK
Endothelial Nitric Oxide Synthase &Portal Hypertension$71,500
R03 · FY2002 · DK
REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION$127,629
K08 · FY2001 · DK
Endothelial Nitric Oxide Synthase &Portal Hypertension$71,500
R03 · FY2001 · DK
REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION$126,900
K08 · FY2000 · DK